a-syngeneic-mouse-b-cell-lymphoma-model-for-pre-clinical-evaluation

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

The astonishing clinical success of CD19 chimeric antigen receptor (CAR) T-cell therapy has led to the approval of two second generation chimeric antigen ...

University of Manchester

Chimeric antigen receptor (CAR) T cells form part of a broad wave of immunotherapies that are showing promise in early phase cancer clinical trials. This clinical delivery has been based upon preclinical efficacy testing that confirmed the proof of principle of the therapy. However, CAR T-cell therapy does not exist alone as T cells are generally given in combination with patient preconditioning, most commonly in the form of chemotherapy, and may also include systemic cytokine support, both of which are associated with toxicity. Consequently, complete CAR T-cell therapy includes elements where the toxicity profile is well known, but also includes the CAR T cell itself, for which toxicity profiles are largely unknown. With recent reports of adverse events associated with CAR T-cell therapy, there is now concern that current preclinical models may not be fit for purpose with respect to CAR T-cell toxicity profiling. Here, we explore the preclinical models used to validate CAR T-cell function and examine their potential to predict CAR T-cell driven toxicities for the future. 

CAR T-cell therapy: toxicity and the relevance of preclinical models.

Adoptive T cell immunotherapy (ATCT) for cancer entails infusing patients with T cells that recognise and destroy tumour cells. Efficient engraftment of T cells and persistence in the circulation correlate with favourable clinical outcomes. T cells of early differentiation possess an increased capacity for proliferation and therefore persistence, using these cells for ATCT could therefore lead to improved clinical outcomes.

Gray Kueberuwa

Manchester Cancer Research Centre Building,
Department Cancer Sciences,
Manchester Cancer Research Centre Building, Department Cancer Sciences

University of Manchester

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Gray Kueberuwa

.css-o250i3{font-size:18px;font-family:Open Sans,sans-serif;line-height:21.6px;}Manchester Cancer Research Centre Building,Department Cancer Sciences,Manchester Cancer Research Centre Building, Department Cancer Sciences

University of Manchester

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Manchester Cancer Research Centre Building,
Department Cancer Sciences,
Manchester Cancer Research Centre Building, Department Cancer Sciences